Dr Reddy8217;s Laboratories shares gain on generic Zenatane launch

Shares in Dr Reddy8217;s Laboratories Ltd gain 2.1 percent after the company on Thursday said in a statement that it launched Zenatane,a generic version of Accutane drug,following its approval by the United States Food amp; Drug Administration USFDA.

The company added that the drug had 309 million in sales for the most recent twelve months ending January 2013,according to IMS Health.

8220;Assuming an incremental 20-25 percent price drop and 20 percent market share,this could be 50 million per year revenue opportunity for Dr.Reddy8217;s,8221; Morgan Stanley said in a report.